Only China locations: Phase 1 Study of the HS-10365 in Patients With Advanced Solid Tumors

Inclusion criteria: Locally advanced or metastatic cancer patients for who that standard treatment is invalid, unavailable or intolerable. Enrollment will be restricted to participants with evidence of a RET gene alteration.

Sponsor/Collaborator: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Contact and Locations:
Study contact: Shun Lu, MD.
Phone Number: 13601813062

Mechanism of action: Small molecular, oral potent, selective RET inhibitor

Phases: Phase 1

NCT Number: NCT05207787

Status: Recruiting

Back to clinical trials list